First CE-IVD marked AI solution for prognostic risk stratification of breast cancer patients.
June 01, 2022 03:59 ET
|
Stratipath
Stockholm, Sweden, June 01, 2022 (GLOBE NEWSWIRE) -- Stratipath, a global leader in AI-based precision diagnostic solutions, today announced that its AI software for prognostic risk stratification...
QuantuMDx confirm its diagnostic tests remain able to detect all known variants of COVID-19 including the new variant from South Africa, B.1.1.529
November 26, 2021 07:37 ET
|
QuantuMDx Group Ltd
NEWCASTLE UPON TYNE, UK, 26 NOVEMBER 2021. QuantuMDx Group Limited (“QuantuMDx”), today confirms that both its SARS-CoV-2 assays for open PCR platforms and its rapid PCR device, Q-POC™, as well as its...
InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Hugh Rogers, CEO of XPhyto Therapeutics Corp.
June 17, 2021 09:00 ET
|
XPhyto Therapeutics Corp.
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment...
The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay
December 05, 2019 06:00 ET
|
Invivoscribe, Inc.
SAN DIEGO, Dec. 05, 2019 (GLOBE NEWSWIRE) -- For twenty-five years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and...